The Effects of Synbiotic " Bifidobacterium lactis B94 plus Inulin" Addition on Standard Triple Therapy of Helicobacter pylori Eradication in Children

Gonca Handan Ustundag, Halime Altuntas, Yasemin Dilek Soysal, Furuzan Kokturk, Gonca Handan Ustundag, Halime Altuntas, Yasemin Dilek Soysal, Furuzan Kokturk

Abstract

Aim: The aim of this study is to evaluate the effects of the synbiotic Bifidobacterium lactis B94 plus inulin addition to the standard triple therapy on Helicobacter pylori (H. pylori) infection eradication rates.

Methods: Children aged 6-16 years who had biopsy proven H. pylori infection were randomly classified into two groups. The first group received the standard triple therapy consisting of amoxicillin + clarithromycin + omeprazole. The second group was treated with the standard triple therapy and Bifidobacterium lactis B94 (5 × 109 CFU/dose) plus inulin (900 mg) for 14 days, concurrently. Eradication was determined by 14C-urea breath test 4-6 weeks after therapy discontinuation.

Results: From a total of 69 H. pylori infected children (F/M = 36/33; mean ± SD = 11.2 ± 3.0 years), eradication was achieved in 20/34 participants in the standard therapy group and 27/35 participants in the synbiotic group. The eradication rates were not significantly different between the standard therapy and the synbiotic groups [intent-to-treat, 58.8% and 77.1%, resp., p = 0.16; per-protocol, 64.5% and 81.8%, resp., p = 0.19]. There was no difference between the groups in terms of symptom relief (p = 0.193). The reported side effects were ignorable.

Conclusion: Considering the eradication rates, synbiotic addition to therapy showed no superiority over the standard triple therapy conducted alone. This trial is registered with NCT03165253.

Figures

Figure 1
Figure 1
Flow diagram of the patients' progression through the study. 14C-UBT: carbon-14 labelled urea breath test.

References

    1. Suerbaum S., Michetti P. Helicobacter pylori infection. The New England Journal of Medicine. 2002;347(15):1175–1186. doi: 10.1056/NEJMra020542.
    1. Brown L. M. Helicobacter pylori: epidemiology and routes of transmission. Epidemiologic Reviews. 2000;22(2):283–297. doi: 10.1093/oxfordjournals.epirev.a018040.
    1. Us D., Hasçelik G. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population. Journal of Infection. 1998;37(2):148–150. doi: 10.1016/S0163-4453(98)80169-2.
    1. Gurakan F., Kocak N., Yuce A. Helicobacter pylori serology in childhood. TheTurkish Journal of Pediatrics. 1996;38(3):329–334.
    1. Özen A., Ertem D., Pehlivanoglu E. Natural history and symptomatology of Helicobacter pylori in childhood and factors determining the epidemiology of infection. Journal of Pediatric Gastroenterology and Nutrition. 2006;42(4):398–404. doi: 10.1097/01.mpg.0000215307.48169.7b.
    1. Den Hollander W. J., Holster I. L., Van Gilst B., et al. Intergenerational reduction in Helicobacter pylori prevalence is similar between different ethnic groups living in a Western city. Gut. 2015;64(8):1200–1208. doi: 10.1136/gutjnl-2014-307689.
    1. Parsonnet J., Friedman G. D., Vandersteen D. P., et al. Helicobacter pylori infection and the risk of gastric carcinoma. The New England Journal of Medicine. 1991;325(16):1127–1131. doi: 10.1056/NEJM199110173251603.
    1. Eidt S., Stolte M., Fischer R. Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas. Journal of Clinical Pathology. 1994;47(5):436–439. doi: 10.1136/jcp.47.5.436.
    1. Moschovi M., Menegas D., Stefanaki K., Van-Vliet Constantinidou C., Tzortzatou-Stathopoulou F. Primary gastric Burkitt lymphoma in childhood: Associated with Helicobacter pylori? Medical and Pediatric Oncology. 2003;41(5):444–447. doi: 10.1002/mpo.10319.
    1. Kurugoglu S., Mihmanli I., Celkan T., Aki H., Aksoy H., Korman U. Radiological features in paediatric primary gastric MALT lymphoma and association with Helicobacter pylori. Pediatric Radiology. 2002;32(2):82–87. doi: 10.1007/s00247-001-0598-y.
    1. Al Furaikh S. S. Remission of high-grade B-cell lymphoma in a pediatric patient following Helicobacter pylori eradication. Pediatrics International. 2011;53(1):105–107. doi: 10.1111/j.1442-200X.2010.03142.x.
    1. Hung I. F. N., Wong B. C. Y. Assessing the risks and benefits of treating Helicobacter pylori infection. Therapeutic Advances in Gastroenterology. 2009;2(3):141–147. doi: 10.1177/1756283X08100279.
    1. Sugano K., Tack J., Kuipers E. J., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. doi: 10.1136/gutjnl-2015-309252.
    1. Koletzko S., Jones N. L., Goodman K. J., et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. Journal of Pediatric Gastroenterology and Nutrition. 2011;53(2):230–243. doi: 10.1097/mpg.0b013e3182227e90.
    1. Drumm B., Koletzko S., Oderda G. Helicobacter pylori infection in children: A consensus statement. Journal of Pediatric Gastroenterology and Nutrition. 2000;30(2):207–213. doi: 10.1097/00005176-200002000-00020.
    1. Malfertheiner P., Megraud F., O'Morain C. A., et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence consensus report. Gut. 2012;61(5):646–664. doi: 10.1136/gutjnl-2012-302084.
    1. Vilaichone R.-K., Mahachai V., Graham D. Y. Helicobacter pylori Diagnosis and Management. Gastroenterology Clinics of North America. 2006;35(2):229–247. doi: 10.1016/j.gtc.2006.03.004.
    1. Kadayifci A., Buyukhatipoglu H., Savas M. C., Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clinical Therapeutics. 2006;28(11):1960–1966. doi: 10.1016/j.clinthera.2006.11.011.
    1. Oderda G., Shcherbakov P., Bontems P., et al. Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH) Helicobacter. 2007;12(2):150–156. doi: 10.1111/j.1523-5378.2007.00485.x.
    1. Kutluk G., Tutar E., Bayrak A., et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: Any advantage in clarithromycin-resistant strains? European Journal of Gastroenterology and Hepatology. 2014;26(11):1202–1208. doi: 10.1097/MEG.0000000000000190.
    1. Hill C., Guarner F., Reid G., et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014;11(8):506–514. doi: 10.1038/nrgastro.2014.66.
    1. Roberfroid M. Prebiotics: the concept revisited. The Journal of Nutrition. 2007;137(3) supplement 2:830S–837S.
    1. Bhatia S. J., Kochar N., Abraham P., Nair N. G., Mehta A. P. Lactobacillius acidophilus inhibits growth of Campylobacter pylori in vitro. Journal of Clinical Microbiology. 1989;27(10):2328–2330.
    1. Lorca G. L., Wadström T., Font de Valdez G., Ljungh Å. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Current Microbiology. 2001;42(1):39–44. doi: 10.1007/s002840010175.
    1. Sýkora J., Valečková K., Amlerová J., et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. Journal of Clinical Gastroenterology. 2005;39(8):692–698. doi: 10.1097/01.mcg.0000173855.77191.44.
    1. Hurduc V., Plesca D., Dragomir D., Sajin M., Vandenplas Y. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatrica, International Journal of Paediatrics. 2009;98(1):127–131. doi: 10.1111/j.1651-2227.2008.00977.x.
    1. Tolone S., Pellino V., Vitaliti G., Lanzafame A., Tolone C. Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Italian Journal of Pediatrics. 2012;38(1, article no. 63) doi: 10.1186/1824-7288-38-63.
    1. Ahmad K., Fatemeh F., Mehri N., Mayram S. Probiotics for the treatment of pediatric Helicobacter pylori infection: a randomized double blind clinical trial. Iranian Journal of Pediatrics. 2013;23(1):79–84.
    1. Lionetti E., Miniello V. L., Castellaneta S. P., et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Alimentary Pharmacology and Therapeutics. 2006;24(10):1461–1468. doi: 10.1111/j.1365-2036.2006.03145.x.
    1. Islek A., Sayar E., Yilmaz A., Artan R. Bifidobacterium lactis B94 plus inulin for treatment of Helicobacter pylori infection in children: does it increase eradication rate and patient compliance? Acta Gastro-Enterologica Belgica. 2015;78(3):282–286.
    1. Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatrica, International Journal of Paediatrics. 2005;94(12):1747–1751. doi: 10.1080/08035250500252120.
    1. Çekin A. H., Şahintürk Y., Akbay Harmandar F., Uyar S., Yolcular B. O., Çekin Y. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. Turkish Journal of Gastroenterology. 2017;28:3–11.
    1. Peppelenbosch M. P., Ferreira C. V. Immunology of pre- and probiotic supplementation. British Journal of Nutrition. 2009;101(1):2–4. doi: 10.1017/S0007114508020746.
    1. Sarkar A., Mandal S. Bifidobacteria—Insight into clinical outcomes and mechanisms of its probiotic action. Microbiological Research. 2016;192:159–171. doi: 10.1016/j.micres.2016.07.001.
    1. Hütt P., Shchepetova J., Lõivukene K., Kullisaar T., Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. Journal of Applied Microbiology. 2006;100(6):1324–1332. doi: 10.1111/j.1365-2672.2006.02857.x.
    1. Gomi A., Harima-Mizusawa N., Shibahara-Sone H., Kano M., Miyazaki K., Ishikawa F. Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model. Journal of Dairy Science. 2013;96(2):832–837. doi: 10.3168/jds.2012-5950.
    1. Mukai T., Asasaka T., Sato E., Mori K., Matsumoto M., Ohori H. Inhibition of binding of Helicobacter pylorito the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunology and Medical Microbiology. 2002;32(2):105–110.
    1. Gotteland M., Brunser O., Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Alimentary Pharmacology and Therapeutics. 2006;23(8):1077–1086. doi: 10.1111/j.1365-2036.2006.02868.x.
    1. Cruchet S., Obregon M. C., Salazar G., Diaz E., Gotteland M. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition. 2003;19(9):716–721. doi: 10.1016/s0899-9007(03)00109-6.
    1. Szajewska H., Horvath A., Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics. 2015;41(12):1237–1245. doi: 10.1111/apt.13214.
    1. Lau C. S. M., Ward A., Chamberlain R. S. Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: A meta-analysis. Infection and Drug Resistance. 2016;9:275–289. doi: 10.2147/IDR.S117886.
    1. Shafaghi A., Pourkazemi A., Khosravani M., et al. The Effect of probiotic plus prebiotic supplementation on the tolerance and efficacy of Helicobacter pylori eradication quadruple therapy: a randomized prospective double blind controlled trial. Middle East Journal of Digestive Diseases. 2016;8(3):179–188.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi